Abstract

The present disclosure provides methods of enhancing levodopa therapeutic efficacy for the treatment of Parkinson's disease. The present methods can include administration of compounds having a triphenylphosphonium moiety. Advantageously, the present method can mitigate microbial metabolism of levodopa to dopamine in the gut, improve bioavailability of levodopa in brain, and increase dopamine levels in the brain.

IPC Classes  ?

• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 25/16 - Anti-Parkinson drugs
• C07F 9/54 - Quaternary phosphonium compounds
• C07F 9/6503 - Five-membered rings

Abstract

The present invention relates to a novel culture medium for growing methanogenic archaea and producing methane gas using a methanogenic archaeum without exogenous supply of hydrogen or carbon dioxide. More particularly, the invention relates to a method for growing a methanogenic archaeum in a bioreactor in an aerobic atmosphere, preferably in ambient air, to a methane production method, and to a sterilized culture medium for growing a methanogenic archaeum.

IPC Classes  ?

• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present disclosure provides polyphenolic boronates and mitochondria-targeted polyphenolic boronates and pharmaceutical compositions thereof. The present compounds may be useful for treating cancer and reducing or inhibiting cancer cell growth. The present compounds may be useful for reducing or analyzing reactive oxygen and nitrogen species in tumor microenvironment of a cancer. The present compounds may target mitochondria in carcer cells and have improved anti-tumor effect and reduced toxicity.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents
• C07F 5/02 - Boron compounds

Abstract

The present invention relates to the field of oncology. laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking: to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07C 205/59 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
• C07D 207/22 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 487/04 - Ortho-condensed systems
• C12Q 1/6841 - In situ hybridisation

Abstract

The present disclosure provides mitochondria-targeted N-acetylcysteine compounds and pharmaceutical compositions thereof. The present compounds may be useful for treating cancer and enhancing CAR-T cell therapy. The present compounds may be isotopically labeled, which may be useful for labeling and analyzing a sample. The present compounds may target mitochondria in carcer cells and have improved anti-tumor effect and reduced toxicity.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
• A61K 31/66 - Phosphorus compounds
• A61K 31/121 - Ketones acyclic

Abstract

In the present invention, the inventors provide substituted the hydroxyl group in hydroxyurea (HU) with a triphenylphosphonium (TPP) cation attached to an alkyl group with different chain lengths, generating a new class of mitochondria-targeted hydroxyurea compounds (Mito-HUs). Elongating the alkyl side chain length increased the hydrophobicity of Mito-HUs, and correlated with increased inhibition of oxidative phosphorylation, and antiproliferative effects in tumor cells.

IPC Classes  ?

• C07F 9/54 - Quaternary phosphonium compounds
• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a method for feeding a flatworm and to a flatworm extract that is free of human-pathogenic microorganisms and is useful in the pharmaceutical, cosmetic and nutraceutical fields.

IPC Classes  ?

• A61K 35/62 - LeechesWorms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates

Abstract

The present invention relates to novel mutated lactonases, to their uses as well as to compositions containing them.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A61K 38/00 - Medicinal preparations containing peptides
• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates

Abstract

Disclosed is a mutated lactonase belonging to the phosphotriesterase-like lactonase family, which increases the susceptibility of bacteria to antimicrobial agents as compared to the use of antimicrobial agents alone.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A01N 63/50 - Isolated enzymesIsolated proteins
• A61P 31/04 - Antibacterial agents
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor

Abstract

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

IPC Classes  ?

• A61K 31/66 - Phosphorus compounds
• C07F 9/535 - Organo-phosphoranes
• C07F 9/54 - Quaternary phosphonium compounds
• C07C 49/84 - Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
• A61P 35/00 - Antineoplastic agents
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention is related to a method for measuring the variability of the red blood cells deformability of an individual by determining the amount of red blood cells having a tank-treading motion in a population of red blood cells from a tested blood sample of said individual, and comparing the amount to a reference amount. The determination of the amount of red blood cells having a tank-treading motion is carried out using a visualisation means such as a brightfield microscope.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G06T 7/00 - Image analysis
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

In the present invention, the inventors provide substituted the hydroxyl group in hydroxyurea (HU) with a triphenylphosphonium (TPP) cation attached to an alkyl group with different chain lengths, generating a new class of mitochondria-targeted hydroxyurea compounds (Mito-HUs). Elongating the alkyl side chain length increased the hydrophobicity of Mito-HUs, and correlated with increased inhibition of oxidative phosphorylation, and antiproliferative effects in tumor cells.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/66 - Phosphorus compounds
• C07C 273/00 - Preparation of urea or its derivatives, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
• C07C 273/02 - Preparation of urea or its derivatives, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups of urea, its salts, complexes or addition compounds
• C07F 9/54 - Quaternary phosphonium compounds

Abstract

The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers.

IPC Classes  ?

• C07F 9/54 - Quaternary phosphonium compounds
• A61K 31/66 - Phosphorus compounds
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a method for feeding a flatworm and to a flatworm extract that is free of human-pathogenic microorganisms and is useful in the pharmaceutical, cosmetic and nutraceutical fields.

IPC Classes  ?

• A61K 35/62 - LeechesWorms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• C12N 5/07 - Animal cells or tissues

Abstract

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

IPC Classes  ?

• A61K 31/12 - Ketones
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• C07C 50/00 - Quinones
• C07C 50/26 - Quinones containing groups having oxygen atoms singly bound to carbon atoms
• C07C 50/32 - Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings

Abstract

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• C07D 207/22 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07C 205/59 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to an inhalable gaseous medicament containing argon gas for use in combination with a mechanical thrombectomy for treating, reducing or resorbing brain lesions subsequent to an ischaemic stroke in an individual. Preferably, the proportion by volume of argon is between 30 and 79%. The mechanical thrombectomy can be accompanied by a drug-based thrombolysis to dissolve the clot and to thin the blood of the patient.

IPC Classes  ?

• A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.

IPC Classes  ?

• C07F 9/54 - Quaternary phosphonium compounds
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to mito-lonidamine compounds, compositions and methods of use in the treatment of cancer.

IPC Classes  ?

• C07F 9/6503 - Five-membered rings
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Abstract

The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).

IPC Classes  ?

• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to the use of a mutated lactonase from the phosphotriesterase-like lactonase family to increase the sensitivity of bacteria to antimicrobial agents compared to the use of antimicrobial agents alone.

IPC Classes  ?

• A01N 63/50 - Isolated enzymesIsolated proteins
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A01N 47/04 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom containing N—S—C≡Hal3 groups
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof

Abstract

Disclosed are mutated phosphotriesterase enzymes with improved stability and activity, as well as their use in particular for degrading organophosphorus compounds.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A01N 63/50 - Isolated enzymesIsolated proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers.

IPC Classes  ?

• C07F 9/54 - Quaternary phosphonium compounds
• A61K 31/66 - Phosphorus compounds
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers.

IPC Classes  ?

• A61K 31/66 - Phosphorus compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07F 9/54 - Quaternary phosphonium compounds

Abstract

The invention is related to a method for measuring the variability of the red blood cells deformability of an individual by determining the amount of red blood cells having a tank-treading motion in a population of red blood cells from a tested blood sample of said individual, and comparing the amount to a reference amount. The determination of the amount of red blood cells having a tank-treading motion is carried out using a visualisation means such as a brightfield microscope.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to mito-lonidamine compounds, compositions and methods of use in the treatment of cancer.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
• C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings

Goods & Services

Adhesives for stationery or household purposes; Decoration and art materials and media; Filtering materials of paper; Works of art and figurines of paper and cardboard, and architects' models; Stationery and educational supplies; Paper and cardboard; Printed matter; Bags and articles for packaging, wrapping and storage of paper, cardboard or plastics. Business assistance, management and administrative services; Business analysis, research and information services; Advertising, marketing and promotional services. Packaging and storage of goods; Distribution by pipeline and cable; Rental services related to transportation and storage; Vehicle parking and storage; Transport; Parking and vehicle storage, mooring. Publishing and reporting; Education, entertainment and sport services; Translation and interpretation; Education, entertainment and sports.

Abstract

The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.

IPC Classes  ?

• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine

Abstract

The invention relates to mutated phosphotriesterase enzymes that have improved stability and activity, as well as to the use of same particularly for degrading organophosphorus compounds.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A61K 38/46 - Hydrolases (3)

Abstract

The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.

IPC Classes  ?

• C07F 9/54 - Quaternary phosphonium compounds
• A61K 31/66 - Phosphorus compounds
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms

Abstract

The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.

IPC Classes  ?

• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine

Abstract

The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.

IPC Classes  ?

• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
• C07C 39/02 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
• C07C 39/06 - Alkylated phenols
• C07C 39/10 - Polyhydroxy benzenesAlkylated derivatives thereof

Abstract

The present disclosure relates to a sample holding micro vice and a sample holding system for coupled transmission electron microscopy (TEM) and atom-probe tomography (APT) analyses. The sample holding micro vice (3) configured to support a tomographic TEM grid (2) intended to receive a sample (6), comprises a base (301) and a clamp. The base (301) comprises a mounting rod (302) configured to engage the sample holding micro vice (3) into the APT device; a base plate (314) fixed perpendicularly to the mounting rod (302); a flat part (303) disposed perpendicularly to the base plate (314) and on the base plate, said flat part (303) comprising a socket (306) having a shape complementary to the tomographic TEM grid (2) to receive the tomographic TEM grid (2) wherein the socket has a depth equal or less than the thickness of the tomographic TEM grid. The clamp (304) has a flat face (308) adapted to maintain the tomographic TEM grid (2) in the socket (306).

IPC Classes  ?

• H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support
• H01J 37/285 - Emission microscopes, e.g. field-emission microscopes

Abstract

The invention relates to a method for modelling a part made of bone tissue, in which: an automated means represents the part with voxels (12), and certain voxels are selected from among the latter to be associated with one surface of the part; for at least some of the selected voxels, the means determines a segment that passes through the centre of the voxel and a point of intersection between the segment and one surface of the voxel, in order to identify a point (H) located on the segment and on or in the voxel; and the means forms a mesh including the identified points (H).

IPC Classes  ?

• G06T 17/20 - Wire-frame description, e.g. polygonalisation or tessellation

Abstract

The present invention relates to the use of a substance selected from the group consisting of avermectins and milbemycins, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment of a Flavivirus infection, preferably an infection caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus). The antiviral medicament of the present invention is suitable for oral administration to a Flavivirus-infected subject, such as a human being or other mammal.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline

Abstract

The present invention relates to a method for manufacturing ultra-porous photocatalytic materials, to the ultra-porous photocatalytic materials obtained by such a method, as well as to the uses thereof for producing hydrogen, treating wastewater and polluted water, treating polluted air, or furthermore to the use of same as catalytic membranes in fuel cells. Finally, a last aim of the invention relates to articles chosen among hydrogen production devices, self-cleaning glass panes and antipollution walls.

IPC Classes  ?

• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 35/10 - Solids characterised by their surface properties or porosity
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts

Abstract

The present invention concerns novel aminoacids derivatives, in particular some aminoacid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.

IPC Classes  ?

• C07D 513/04 - Ortho-condensed systems
• A61K 31/729 - AgarAgaroseAgaropectin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents